PIRAMAL CRITICAL CARE

First Pediatric Dopamine Hydrochloride Formulation Receives MHRA Approval for Treating Hypotension in Children

• BrePco Biopharma and Piramal Critical Care have received MHRA approval for Neoatricon, the first pediatric-specific dopamine hydrochloride formulation for treating hypotension in neonates, infants, and children. • Neoatricon addresses a critical gap in pediatric care by providing age-appropriate, ready-to-use solutions in two concentrations (1.5mg/mL and 4.5mg/mL), eliminating the risks associated with modifying adult formulations. • Piramal Critical Care has secured commercialization rights for the EU, UK, and Norway, marking the company's expansion into a new therapeutic area with potential to significantly improve outcomes for vulnerable pediatric patients.